CalciMedica Inc
For the period ended Mar 31, 2024. Filed May 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 13, 2024
CALC$1.37-9.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities: | ||
| Net income (loss) | $130 | $(19,288) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 414 | 11,126 |
| Depreciation | 15 | 13 |
| Change in the fair value of warrant liability | (5,590) | (1,146) |
| Change in the fair value of convertible promissory notes | - | (2,022) |
| Transaction costs associated with warrants | 776 | — |
| Non-cash interest expense | - | 110 |
| Accretion of discount on short-term investment | (163) | (2) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current and non-current assets | (537) | 129 |
| Accounts payable | 129 | (1,040) |
| Accrued expenses and other liabilities | 111 | 6,765 |
| Net cash used in operating activities | (4,715) | (5,355) |
| Investing activities: | ||
| Purchase of investments | (17,853) | — |
| Maturity of investments | 4,750 | 4,750 |
| Net cash provided by (used in) investing activities | (13,103) | 4,750 |
| Financing activities: | ||
| Proceeds from issuance of common stock, net of issuance costs | 19,043 | 10,340 |
| Acquisition of stock of Graybug, net of cash | — | 14,856 |
| Merger transaction costs | — | (1,681) |
| Net cash provided by financing activities | 19,043 | 23,515 |
| Net increase in cash and cash equivalents | 1,225 | 22,910 |
| Cash, cash equivalents and restricted cash at beginning of period | 5,530 | 1,476 |
| Cash and cash equivalents at end of period | $6,755 | $24,386 |
| Supplemental cash flow information: | ||
| Conversion of Series A, B, C-1, C-2 and D convertible preferred stock to common stock | $— | $62,071 |
| Issuance of common stock to Graybug stockholders as a result of the Merger | $— | $29,218 |
| Short-term investments assumed in the Merger | $— | $9,776 |
| Prepaid expenses and other current assets assumed in the Merger | $— | $2,096 |
| Accounts payable and accrued liabilities assumed in the Merger | $— | $2,258 |
| Conversion of C-2 warrants to common stock | $— | $442 |
| Conversion of convertible promissory notes to common stock | $— | $3,245 |
| Conversion of convertible promissory note warrants to common stock | $— | $841 |
| Merger transaction costs in accounts payable | $— | $206 |
| Merger transactions costs in accrued expenses | $— | $2,703 |
| Financing costs included in accounts payable | $32 | $297 |
| Financing costs included in accrued expenses | $32 | $— |
| Reclassification of warrant liability to equity | $— | $216 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.